BioLineRx Ltd.(BLRX)Earnings, Financials & Key Ratios
BLRX•NASDAQ
$3.17
Price updated Jun 27, 2026
AboutBioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Show more
- Revenue$1M-95.9%
- EBITDA-$10M+39.8%
- Net Income-$1M+87.2%
- EPS (Diluted)-0.29-141.7%
- Gross Margin36.19%-46.8%
- EBITDA Margin-827.46%-1365.3%
- Operating Margin-871.78%-1136.2%
- Net Margin-99.58%-212.5%
- ROE-6.44%+90.7%
BLRX Price & Volume
BioLineRx Ltd. (BLRX) stock price & volume — 10-year historical chart
Loading chart...
Stalled Commercial Launch Threatens Operational Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"BioLineRx faces a critical inflection point as the commercial transition of APHEXDA has failed to generate consistent revenue, with quarterly figures collapsing from $11.7M in 2024Q4 to $477K in 2026Q1. The company's reliance on milestone-dependent income has left it with a precarious $2.5M cash balance, necessitating potential dilutive financing to sustain operations. Investors should monitor the firm's ability to stabilize its cost structure against an accumulated deficit of $402.6M, which continues to erode shareholder equity."
Verdict Logic
the company's cash position has dwindled to $2.5M as of 2026Q1, creating an imminent liquidity risk that likely necessitates further dilutive capital raises.
BLRX Growth Metrics
BioLineRx Ltd. (BLRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-93.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-161.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-4773.56%
Return on Capital
10 Years-59.94%
5 Years-66.75%
3 Years-81.85%
Last Year-39.66%
BLRX Recent Earnings
BioLineRx Ltd. (BLRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (44%)
Q2 2026Latest
Mar 23, 2026Metric
Actual
Est
EPS
$0.34+32.0%
$0.50
Rev
$514,000+0.0%
$514,000
Q4 2025
Nov 24, 2025Metric
Actual
Est
EPS
$0.22+46.3%
$0.41
Rev
$427,000-36.3%
$670,000
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$1.00-185.7%
$0.35
Rev
$304,000-60.9%
$776,670
Q2 2025
May 27, 2025Metric
Actual
Est
EPS
$1.39+265.5%
$0.84
Rev
$255,000-86.0%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 23, 2026 | $0.34vs $0.50+32.0% | $514,000vs $514,000+0.0% |
| Q4 2025 | Nov 24, 2025 | $0.22vs $0.41+46.3% | $427,000vs $670,000-36.3% |
| Q3 2025 | Aug 14, 2025 | $1.00vs $0.35-185.7% | $304,000vs $776,670-60.9% |
| Q2 2025 | May 27, 2025 | $1.39vs $0.84+265.5% | $255,000vs $2M-86.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for BioLineRx Ltd. (BLRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.17 | $13.77M | -10.91 | -95.89% | -99.58% | -6.44% | — | |
| $55.83 | $8.55B | 20.16 | 87.32% | 65.95% | 87.36% | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — | |
| $4.81 | $305.74M | -4.08 | 0.78% | -44.79% | -147.8% | — | |
| $8.75 | $2.03B | 14.58 | 19.63% | 32.43% | 38.97% | — | |
| $35.26 | $2.35B | -9.04 | -78.63% | -34596.22% | -50.72% | — |
Compare BLRX vs Peers
BioLineRx Ltd. (BLRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BLRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BLRX Frequently Asked Questions
BioLineRx Ltd. (BLRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is BioLineRx Ltd.'s revenue?
BioLineRx Ltd. (BLRX) reported $1.4M in revenue for fiscal year 2025.
How fast is BioLineRx Ltd. growing?
BioLineRx Ltd. (BLRX) saw revenue decline by 95.9% over the past year.
Is BLRX profitable?
BioLineRx Ltd. (BLRX) reported a net loss of $8.9M for fiscal year 2025.
Dividend & Returns
What is BLRX's return on equity?
BioLineRx Ltd. (BLRX) has a return on equity (ROE) of -6.4%. Negative ROE indicates the company is unprofitable.
What is BioLineRx Ltd.'s free cash flow?
BioLineRx Ltd. (BLRX) had negative free cash flow of $7.8M in fiscal year 2025, likely due to heavy capital investments.